Aktuellt
SENASTE
Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a negative revision reflecting the slow launch progress and a more stretched funding outlook. Our Base Case is SEK100 (175) with a Bull Case of SEK200 (400) and a Bear Case of SEK15 (45).
LÄS MER
